MagForce Nanotechnologies Completes Patient Recruitment For Pivotal Glioblastoma Study (Medical News Today)

MagForce Nanotechnologies AG (FWB:MF6) has successfully completed patient recruitment for its study on recurrent glioblastoma, which is of critical importance for demonstrating the efficacy of its proprietary Nano-Cancer® therapy.
(read the story…)

Related items

• MagForce Nanotechnologies Completes Patient Recruitment for Pivotal Glioblastoma Study (Business Wire via Yahoo! Finance)
• Nanostart-Owned MagForce Nanotechnologies AG: Application Submitted For EU Regulatory Approval Of Nano-Cancer(R) Therapy (Medical News Today)
• MagForce Nanotechnologies applies for EU regulatory approval of its Nano-Cancer therapy (News-Medical-Net)
• MagForce Nanotechnologies AG Applies For European Regulatory Approval Of Its Nano-Cancer(R) Therapy (Medical News Today)
• MagForce Nanotechnologies initiates conformity assessment procedure for its Nano-Cancer therapy (News-Medical-Net)

Tags: cancer, cancer therapy, FWB, magforce, nano, Nano-Cancer, nanotech, nanotechnologie, nanotechnologies, patient, patient recruitment, recruitment, recurrent glioblastoma

This entry was posted on Wednesday, September 23rd, 2009 at 11:21 pm and is filed under Business.